398 related articles for article (PubMed ID: 11861813)
21. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.
Darwich AS; Neuhoff S; Jamei M; Rostami-Hodjegan A
Curr Drug Metab; 2010 Nov; 11(9):716-29. PubMed ID: 21189140
[TBL] [Abstract][Full Text] [Related]
22. CYP3A4, CYP3A5, and MDR1 in human small and large intestinal cell lines suitable for drug transport studies.
Engman HA; Lennernäs H; Taipalensuu J; Otter C; Leidvik B; Artursson P
J Pharm Sci; 2001 Nov; 90(11):1736-51. PubMed ID: 11745731
[TBL] [Abstract][Full Text] [Related]
23. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
24. PXR/CYP3A4-humanized mice for studying drug-drug interactions involving intestinal P-glycoprotein.
Holmstock N; Gonzalez FJ; Baes M; Annaert P; Augustijns P
Mol Pharm; 2013 Mar; 10(3):1056-62. PubMed ID: 23360470
[TBL] [Abstract][Full Text] [Related]
25. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine.
Lown KS; Mayo RR; Leichtman AB; Hsiao HL; Turgeon DK; Schmiedlin-Ren P; Brown MB; Guo W; Rossi SJ; Benet LZ; Watkins PB
Clin Pharmacol Ther; 1997 Sep; 62(3):248-60. PubMed ID: 9333100
[TBL] [Abstract][Full Text] [Related]
26. Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers.
Raeissi SD; Hidalgo IJ; Segura-Aguilar J; Artursson P
Pharm Res; 1999 May; 16(5):625-32. PubMed ID: 10350002
[TBL] [Abstract][Full Text] [Related]
27. Transport of 5,5-diphenylbarbituric acid and its precursors and their effect on P-gp, MRP2 and CYP3A4 in Caco-2 and LS180 cells.
Fan J; Maeng HJ; Du Y; Kwan D; Pang KS
Eur J Pharm Sci; 2011 Jan; 42(1-2):19-29. PubMed ID: 20955791
[TBL] [Abstract][Full Text] [Related]
28. Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4.
Wang E; Lew K; Barecki M; Casciano CN; Clement RP; Johnson WW
Chem Res Toxicol; 2001 Dec; 14(12):1596-603. PubMed ID: 11743742
[TBL] [Abstract][Full Text] [Related]
29. Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs.
Patel J; Mitra AK
Pharmacogenomics; 2001 Nov; 2(4):401-15. PubMed ID: 11722289
[TBL] [Abstract][Full Text] [Related]
30. The consequence of regional gradients of P-gp and CYP3A4 for drug-drug interactions by P-gp inhibitors and the P-gp/CYP3A4 interplay in the human intestine ex vivo.
Li M; de Graaf IA; van de Steeg E; de Jager MH; Groothuis GM
Toxicol In Vitro; 2017 Apr; 40():26-33. PubMed ID: 27939799
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells.
Takanaga H; Ohnishi A; Matsuo H; Sawada Y
Biol Pharm Bull; 1998 Oct; 21(10):1062-6. PubMed ID: 9821810
[TBL] [Abstract][Full Text] [Related]
32. Dextran sulfate sodium-induced colitis and ginseng intervention altered oral pharmacokinetics of cyclosporine A in rats.
Yang Y; Hu N; Gao XJ; Li T; Yan ZX; Wang PP; Wei B; Li S; Zhang ZJ; Li SL; Yan R
J Ethnopharmacol; 2021 Jan; 265():113251. PubMed ID: 32810615
[TBL] [Abstract][Full Text] [Related]
33. Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport.
Katoh M; Nakajima M; Yamazaki H; Yokoi T
Eur J Pharm Sci; 2001 Feb; 12(4):505-13. PubMed ID: 11231118
[TBL] [Abstract][Full Text] [Related]
34. Contributions of CYP3A4, P-glycoprotein, and serum protein binding to the intestinal first-pass extraction of saquinavir.
Mouly SJ; Paine MF; Watkins PB
J Pharmacol Exp Ther; 2004 Mar; 308(3):941-8. PubMed ID: 14718607
[TBL] [Abstract][Full Text] [Related]
35. Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4.
Achira M; Suzuki H; Ito K; Sugiyama Y
AAPS PharmSci; 1999; 1(4):E18. PubMed ID: 11741214
[TBL] [Abstract][Full Text] [Related]
36. Crohn's Disease Is Associated with Decreased CYP3A4 and P-Glycoprotein Protein Expression.
Wilson A; Urquhart BL; Ponich T; Chande N; Gregor JC; Beaton M; Kim RB
Mol Pharm; 2019 Sep; 16(9):4059-4064. PubMed ID: 31393129
[TBL] [Abstract][Full Text] [Related]
37. Effect of furanocoumarin derivatives in grapefruit juice on the uptake of vinblastine by Caco-2 cells and on the activity of cytochrome P450 3A4.
Ohnishi A; Matsuo H; Yamada S; Takanaga H; Morimoto S; Shoyama Y; Ohtani H; Sawada Y
Br J Pharmacol; 2000 Jul; 130(6):1369-77. PubMed ID: 10903978
[TBL] [Abstract][Full Text] [Related]
38. Effect of pluronic F68 block copolymer on P-glycoprotein transport and CYP3A4 metabolism.
Huang J; Si L; Jiang L; Fan Z; Qiu J; Li G
Int J Pharm; 2008 May; 356(1-2):351-3. PubMed ID: 18242899
[TBL] [Abstract][Full Text] [Related]
39. N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide (GF120918) as a chemical ATP-binding cassette transporter family G member 2 (Abcg2) knockout model to study nitrofurantoin transfer into milk.
Wang L; Leggas M; Goswami M; Empey PE; McNamara PJ
Drug Metab Dispos; 2008 Dec; 36(12):2591-6. PubMed ID: 18799806
[TBL] [Abstract][Full Text] [Related]
40. P-glycoprotein potentiates CYP3A4-mediated drug disappearance during Caco-2 intestinal secretory detoxification.
Chan LM; Cooper AE; Dudley AL; Ford D; Hirst BH
J Drug Target; 2004; 12(7):405-13. PubMed ID: 15621665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]